Title:
CRISPR-Cas system: from diagnostic tool to potential antiviral treatment

dc.contributor.authorAishwarya Rajan
dc.contributor.authorStuti Shrivastava
dc.contributor.authorJanhawi
dc.contributor.authorAkhilesh Kumar
dc.contributor.authorAlok Kumar Singh
dc.contributor.authorPankaj Kumar Arora
dc.date.accessioned2026-02-07T10:59:01Z
dc.date.issued2022
dc.description.abstractAbstract: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic tools for treating viral infections including HIV, Influenza, and SARS-CoV-2. There are several major challenges to be overcome before this technology can be applied routinely in clinical settings, such as finding a suitable delivery tool, toxicity, and immunogenicity, as well as off-target effects. This review also discusses ways to deal with the challenges associated with Crisper-Cas technology. Key points: • Crisper technology is being applied to diagnose infectious and non-infectious diseases. • A new generation of CRISPR-Cas-based assays has been developed which detect pathogens within minutes, providing rapid diagnosis of diseases. • Crispr-Cas tools can be used to combat viral infections, specifically HIV, influenza, and SARS-CoV-2. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
dc.identifier.doi10.1007/s00253-022-12135-2
dc.identifier.issn1757598
dc.identifier.urihttps://doi.org/10.1007/s00253-022-12135-2
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/40791
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.subjectCrispr-Cas
dc.subjectHIV
dc.subjectInfluenza
dc.subjectSARS-CoV-2
dc.titleCRISPR-Cas system: from diagnostic tool to potential antiviral treatment
dc.typePublication
dspace.entity.typeReview

Files

Collections